Ocular Therapeutix (OCUL) Common Equity (2013 - 2026)

Ocular Therapeutix's Common Equity history runs 14 years deep, the most recent figure standing at $581.6 million for Q1 2026.

• In Q1 2026, Common Equity rose 118.69% year-over-year to $581.6 million; the TTM figure through Mar 2026 stood at $581.6 million (up 118.69% YoY), while the FY2025 annual figure was $654.3 million, up 107.49% from the prior year.
• Common Equity was $581.6 million for Q1 2026 at Ocular Therapeutix, down from $654.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $654.3 million in Q4 2025 to a low of $3.1 million in Q2 2023.
• Historically, Common Equity has averaged $226.9 million across 5 years, with a median of $258.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 95.31% in 2023, then surged 12135.02% in 2024.
• A 5-year view of Common Equity shows it stood at $35.4 million in 2022, then surged by 157.59% to $91.1 million in 2023, then soared by 246.03% to $315.3 million in 2024, then surged by 107.49% to $654.3 million in 2025, then fell by 11.12% to $581.6 million in 2026.
• The last three Common Equity figures came in at $581.6 million (Q1 2026), $654.3 million (Q4 2025), and $258.2 million (Q3 2025), per Business Quant data.